The US Food and Drug Administration (FDA) has declined to approve a treatment that combines the psychedelic drug midomafetamine with assisted therapy (MDMA-AT) for the treatment of posttraumatic stress disorder (PTSD). In a statement, drug manufacturer Lykos Therapeutics said the agency had issued a complete response letter…
